Search | Clinical Trials Finder

Conditions: Turner's Syndrome
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 10 Years and older
Enrollment: 1,017 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Fragile X Syndrome
Interventions: Aripiprazole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 35 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Intellectual Disability, Fragile X Syndrome, Down Syndrome, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate Oral Solution; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 6 Years to 24 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Cincinnati, Ohio

Conditions: Prader-Willi Syndrome
Interventions: Placebo, Tesomet; Other · Drug
Lead sponsor: Saniona; Industry
Eligibility: 13 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Burden, Caregiver
Interventions: Yoga; Support Group; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prader-willi Syndrome
Interventions: rimonabant, placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Fragile X Syndrome
Interventions: Follicle Aspiration; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Down Syndrome (DS)
Interventions: MIB-626, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Down Syndrome, Alzheimer Disease, Dementia
Interventions: Not listed
Lead sponsor: University of Southern California; Other
Eligibility: 25 Years to 55 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 18
States / cities: Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more

Conditions: Down Syndrome, Amyloid Beta-protein
Interventions: Florbetaben (BAY94-9172); Drug
Lead sponsor: Lantheus Biosciences Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Sun City, Arizona • New Haven, Connecticut

Conditions: Down Syndrome, Obstructive Sleep Apnea
Interventions: Open-ended semi-structured interviews; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fragile X Syndrome
Interventions: AFQ056; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Nashville, Tennessee

Conditions: Fragile X Syndrome
Interventions: STX107; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more

Conditions: Down Syndrome, Adaptive Behavior, Quality of Life
Interventions: The MapHabit System; Device
Lead sponsor: MapHabit, Inc.; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Interventions: Not listed
Lead sponsor: Richard Frye; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Down Syndrome, Trisomy 21
Interventions: EXPO, EXPO Extended, EXPO Foundations; Behavioral
Lead sponsor: Colorado State University; Other
Eligibility: 36 Months to 72 Months
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Down Syndrome, Trisomy 21
Interventions: JASPER; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 24 Months to 48 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fragile X Syndrome
Interventions: arbaclofen, placebo; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 24
States / cities: Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more

Conditions: Down Syndrome, Chromosome Abnormalities
Interventions: Ultrasound, Serum screen; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 38,000 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 10
States / cities: Denver, Colorado • Boston, Massachusetts • Royal Oak, Michigan + 6 more

Conditions: Adolescent Behavior, Intellectual Disability, Down Syndrome, Physical Activity
Interventions: Group Exercise Sessions, Individual Support Sessions, Facebook Group; Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 10 Years to 21 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lawrence, Kansas

Conditions: Leukemia
Interventions: PEG-IFNá-2a; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypotonia, Muscle, Obstructive Sleep Apnea, Nasal Airway Obstruction
Interventions: Self-Supporting Nasopharyngeal Airway (ssNPA); Device
Lead sponsor: University of Michigan; Other
Eligibility: 3 Years to 23 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Turner Syndrome: Genotype and Phenotype

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome

Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

Social Support and Stress Reduction for Caregivers of Young Adults With IDD

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome

Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

Trial-Ready Cohort-Down Syndrome (TRC-DS)

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

Investigating the Experience of Living With Down Syndrome and Obstructive Sleep Apnea Syndrome (Stage 1)

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

Life Skills Improved in Children With Down Syndrome After Using Assistive Technology

Patterns of Neurodevelopmental Disorders

Executive Function Play Opportunities for Children With Down Syndrome

JASPER Intervention in Down Syndrome

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome

Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters

Promotion of Physical Activity in Adolescents With Intellectual and Developmental Disabilities

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Long-term Evaluation of Nasopharyngeal Airway in Hypotonia